Analyst Price Targets — RXST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 11:12 am | Thomas Stephan | Stifel Nicolaus | $9.00 | $7.57 | TheFly | RxSight price target lowered to $9 from $10 at Stifel |
| February 26, 2026 11:09 am | David Saxon | Needham | $13.00 | $8.81 | StreetInsider | Needham Reiterates Buy Rating on RxSight Inc. (RXST) |
| January 20, 2026 11:45 am | — | Piper Sandler | $11.00 | $9.81 | TheFly | RxSight price target raised to $11 from $10 at Piper Sandler |
| December 2, 2025 11:39 am | — | Morgan Stanley | $10.00 | $11.65 | TheFly | RxSight price target raised to $10 from $9 at Morgan Stanley |
| November 6, 2025 4:57 pm | — | Stifel Nicolaus | $10.00 | $8.73 | TheFly | RxSight price target raised to $10 from $8 at Stifel |
| October 29, 2024 8:11 am | Anthony Crowdell | Mizuho Securities | $67.00 | $52.00 | Benzinga | This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday |
| October 29, 2024 8:11 am | Curry Baker | Guggenheim | $52.00 | $52.00 | Benzinga | This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday |
| October 29, 2024 8:11 am | Adam Seiden | Barclays | $110.00 | $52.00 | Benzinga | This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday |
| October 29, 2024 3:09 am | Young Li | Jefferies | $72.00 | $50.25 | StreetInsider | Jefferies Starts RxSight Inc. (RXST) at Buy |
| September 23, 2024 5:33 am | Ryan Zimmerman | BTIG | $59.00 | $52.98 | StreetInsider | BTIG Reiterates Buy Rating on RxSight Inc. (RXST) |
Latest News for RXST
WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that over 300,000 Light Adjustable Lens® (LAL®) implants have been performed since launch, marking a significant milestone in the company's pursuit to make customized vision correction widely available to patients.
Shares of RxSight, Inc. (NASDAQ: RXST - Get Free Report) fell 3.7% on Tuesday. The company traded as low as $6.75 and last traded at $6.76. 430,271 shares were traded during trading, a decline of 45% from the average session volume of 784,773 shares. The stock had previously closed at $7.02. Analyst Ratings Changes A
ALISO VIEJO, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, April 16, 2026, at 8:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at…
RxSight, Inc. (NASDAQ: RXST - Get Free Report) has received a consensus recommendation of "Reduce" from the fifteen analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company. The average
RxSight, Inc. (NASDAQ: RXST - Get Free Report) was the target of a large increase in short interest in February. As of February 13th, there was short interest totaling 5,358,739 shares, an increase of 29.3% from the January 29th total of 4,144,635 shares. Approximately 14.4% of the company's stock are sold short. Based on an average
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RXST.
U.S. House Trading
No House trades found for RXST.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.